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RAISE HIGH&BE PROUD! Here are nearly 100 COVID-19 publications from GW faculty.
Epidemiology/Transmission
An up-to-date review of viral, host, and environmental factors for transmission of SARS-CoV-2
shows respiratory transmission is dominant and fomite transmission is unusual.
Brigham and Women’s Hospital released information about a COVID-19 cluster in their
institution. Infection Control investigation found that these may be contributing factors:






Many patients were not masked during clinical care/interactions with staff
Providers were inconsistent in their use of eye protection during patient encounters
The first patient who tested positive had received an aerosol generating procedure prior to the
positive test result
A staff member with mild symptoms, consistent with historical seasonal allergies, did not
appreciate those symptoms as potentially related to COVID-19 and continued to work
Lack of physical distancing among staff while unmasked while eating

COVID-19 re-infection has been proven by a phylogenetically distinct SARS-coronavirus-2
strain confirmed by whole genome sequencing. This gives rise to concern that SARS-CoV-2 may
continue to circulate among the human populations despite herd immunity due to natural
infection or vaccination.
A study evaluating COVID-19 in homeless shelters found symptomatic and asymptomatic cases
suggesting the need for routine viral testing outside of clinical settings for homeless populations.
Outbreak of COVID-19 in a nursing home associated with aerosol transmission as a result of
inadequate ventilation.
Variolation* could be a welcome, unexpected benefit of universal facial masking.
* Variolation was a process whereby people who were susceptible to smallpox were inoculated with
material taken from a vesicle of a person with smallpox, with the intent of causing a mild infection and
subsequent immunity.

COVID-19 transmission to health care providers (HCP) was associated with medical exposures
currently considered lower-risk and multiple extra-occupational exposures, while exposures
associated with proper use of appropriate PPE were protective.
HCP transmission was associated with non-aerosol-generating contact with COVID-19 patients
(OR 1.4) and extra-occupational exposures including gatherings of ten or more, patronizing
restaurants or bars, and public transportation (ORs 3.1-16.2). Respirator use during aerosolgenerating procedures was associated with lower odds of HCP infection (OR 0.4), as was
exposure to intensive care and dedicated COVID units, negative pressure rooms, and personal
protective equipment (PPE) observers (ORs 0.4-0.7).

Evaluation of hazardous air pollutant exposure as a contributing factor to COVID-19 mortality in
the US found that an increase in the respiratory hazard index is associated with a 9% increase in
COVID-19 mortality.
Testing
Evaluation of rapid testing studies needs further evaluation based on clinical outcomes as most
reports are based on remnant laboratory samples. Antigen testing was highly variable with
average sensitivity of 56.2% and specificity of 99.5%. Rapid molecular assays had an average
sensitivity of 95.2% and specificity of 98.9%.
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The Rockefeller Foundation report proposes strategies on the effective use of innovative, largescale COVID testing with a focus on tailoring to local circumstances and risk tolerances.
A comparison of saliva and oro-nasopharyngeal swab found saliva samples were acceptable for
use in COVID testing. The sensitivity and positive predictive value of saliva samples were
85.2%, specificity and negative predictive value were 89.2%
OBGYN
A study evaluating COVID-19 in breastmilk found that breast milk may not be a source of
infection.
CDC report of 598 hospitalized pregnant women with COVID-19: 55% were asymptomatic at
admission and that severe illness among symptomatic pregnant women resulted in ICU
admissions (16%), mechanical ventilation (8%), and death (1%). Pregnancy losses occurred for
2% of pregnancies. Another CDC report found higher prevalence of pre-pregnancy obesity and
gestational diabetes among pregnant women hospitalized for COVID-19–related illness.
Internal Medicine
Massachusetts General Hospital researchers developed the COVID-19 Acuity Score (CoVA),
which predicts hospital admission, critical illness or death within seven days.
WHO update on long-term effects of COVID-19 includes data on cardiovascular, pulmonary,
brain and nervous system, mental health and musculoskeletal complications.
Evaluation of SARS-CoV-2 in persons with HIV infection found the risk for poor outcomes was
higher in those with comorbidities (older age, chronic lung disease and hypertension) and lower
CD4 cell count (<200 cells/mm3).
Young adults (18 to 34 years) hospitalized with COVID-19 experienced substantial rates of
adverse outcomes: 21% required intensive care, 10% required mechanical ventilation, and 2.7%
died. Morbid obesity, hypertension, and diabetes were common and associated with greater risks
of adverse events. More than half of patients requiring hospitalization were Black or Hispanic.
The risk factors which predict higher overall mortality among patients with chronic liver disease
and COVID-19 were alcohol-related liver disease, decompensated cirrhosis, and hepatocellular
carcinoma.
SREBP-2 (sterol regulatory element binding protein-2) is a possible indicator for severity
diagnosis and potential therapeutic target for preventing cytokine storm and lung damage.
Cardiology
Several studies have documented SARS CoV-2 myocardial damage: MRIs of recently recovered
patients found cardiac involvement in 78% of patients and ongoing myocardial inflammation in
60%, independent of preexisting conditions, severity and overall course of the acute illness.
Another found infection of iPSC-derived cardiac cells with disruption of structural proteins.
In-hospital mortality was more than 3 times higher in COVID-19 positive ACS patients than in
COVID-19 negative ACS patients. Importantly, 75% deceased COVID-19 positive ACS patients
had involvement of multiple organ systems in addition to cardiac manifestations, thus indicating
a systemic vascular damage.
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Neurology
Review of neurological complications of COVID-19.
A literature review of stroke and COVID-19 found large vessel occlusion was twice as frequent
(46.9%) as previously reported and was high across all age groups, even in the absence of risk
factors or comorbidities.
Case report of 3 patients without previous neurologic or autoimmune disorders who were
diagnosed with myasthenia gravis after the onset of COVID-19 and one report of acute
transverse myelitis in COVID-19 infection.
Pediatrics
A Korean study of COVID-19 in children found symptom screening failed to identify most
COVID-19 cases in children, and SARS-CoV-2 RNA in children is detected for a long time
(mean of 17.6 days).
CDC report on SARS-CoV-2 Infections among young children acquired in child care settings
found transmission to their household members. Transmission was observed from two of three
children with confirmed, asymptomatic COVID-19.
Among 121 SARS-CoV-2–associated deaths among persons aged <21 years reported to CDC by
July 31, 2020, 10% were infants and 70% were aged 10–20 years. Hispanic, non-Hispanic Black
and non-Hispanic American Indian/Alaskan Native persons accounted for 78% of these deaths;
33% of deaths occurred outside of a hospital.
Treatment
Updated Infectious Diseases Society of America Guidelines on the Treatment and Management
of Patients with COVID-19. Updates include: new recommendation on the use of remdesivir in
patients with more moderate disease, revised and new recommendations for the use of
dexamethasone and a revised recommendation against the routine use of tocilizumab.
Evaluation of data synthesized from all RCTs available on remdesivir found both 10‐day and
5‐day remdesivir regimens were associated with higher odds of clinical improvement compared
with placebo. But a study of patients hospitalized with moderate COVID-19 pneumonia,
patients randomized to a 5-day course, but not a 10 day course, of remdesivir had a statistically
significant better clinical status compared with standard care.
Administration of systemic corticosteroids (hydrocortisone, methylprednisolone, or
dexamethasone), compared with usual care or placebo, was associated with lower 28-day allcause mortality in critically ill patients with COVID-19. The WHO published Corticosteroid
guidelines.
Studies have looked at sofobuvir and daclatasvir as a potential treatment. One randomized
controlled trial showed significant decrease in duration of hospital stay (6 days vs. 8 days).
Another which looked at sofosbuvir/daclatasvir plus ribavirin, showed no difference in number
or deaths but did show higher incidence of recovery. It is important to note that both had a very
small patient population and larger studies are needed.
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Thymosin drugs had no significant effect on the prevention of COVID‐19 before and after
exposure for medical staff and had increased adverse drug reactions.
In preliminary findings from a RCT, rhG-CSF treatment for patients with COVID-19 with
lymphopenia but no comorbidities did not accelerate clinical improvement, but the number of
patients developing critical illness or dying may have been reduced.
In COVID-19 patients with prolonged PCR positivity, no benefit was seen on the duration of
viral shedding with the combined treatment of leflunomide and IFN α-2a beyond IFN α-2a alone.
Vaccine/Immunity
Initial reports on the Russian (heterologous rAd26 and rAd5 vector-based) COVID-19 vaccine
note a good safety profile. It was also reported to have induced strong humoral and cellular
immune responses in participants.
In a phase 1/2 trial, at 35 days, NVX-CoV2373 (Noravax) appeared to be safe (no serious
adverse events), and elicited immune responses that exceeded levels in Covid-19 convalescent
serum.
In a phase 1 trial, after the second vaccination, the mRNA-1273 vaccine (Moderna) induced antiSARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were
identified.
Longitudinal evaluation and decline of antibody response: Neutralizing antibody (nAb) response
was detected in >95% of cases. The magnitude of the nAb response was dependent upon the
disease severity, but not the kinetics. Declining nAb titers were observed at 3-4 months
Health Systems and Policy
Shift arrangement of medical staff are associated with the mortality of critically ill patients with
COVID-19. Recommendations are to change to allow for more sleep and longer continuity of
care which were associated with reduction of mortality from 77.8% to 36.7%.
NIH COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization
of Convalescent Plasma for the Treatment of COVID-19.

This report was produced by Sara Feeley, PA-C, Himmelfarb Reference Librarians and the GW Covid-19
Intelligence Unit. If you have a question that the Intelligence Unit can assist you with, or if you would
like to provide suggestions or feedback, please email Dr. Lawrence Deyton, lead for the Intelligence at
LDeyton@gwu.edu.
NOTE: Intelligence Reports will be issued monthly with Special Intelligence Reports issued on topics of
immediate interest on an as needed basis. Interim updates are available – see Dr. Hana Akselrod’s
Department of Medicine weekly Infectious Disease Update available on the GW Covid-19 Intelligence
Reports webpage at https://guides.himmelfarb.gwu.edu/SituationReport
Searchable GW Covid-19 resources can be found through the following links:
GW Covid-19 Research Guide: https://guides.himmelfarb.gwu.edu/covid-19
GW Covid-19 Intelligence Reports: https://guides.himmelfarb.gwu.edu/SituationReport
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